ReachMD
CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: reachmd.com
Gdzie słuchać?
Podcasty w aplikacji Replaio Radio Już wkrótcePodcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów
Zainstaluj za darmo
Android prawie 10 mln pobrań · ocena 4,8
iOS niedługo
Odcinki
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach 10.03.2026 5:00
Faculty: Richard Lafayette, MD, FACP Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g...
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN 10.03.2026 6:30
Faculty: Richard Lafayette, MD, FACP Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g...
Emerging Therapies in IgAN: Who Could Benefit the Most? 10.03.2026 7:30
Faculty: Richard Lafayette, MD, FACP Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <...
Emerging Evidence: IgAN Disease-Modifying Agents 10.03.2026 8:00
Faculty: Richard Lafayette, MD, FACP Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <...
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN 10.03.2026 6:30
Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier esc...
IgAN SOC: Strengths and Limits 10.03.2026 3:45
Faculty: Dana Rizk, MD Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0....
Mechanism-Based Targeting: Why APRIL Matters in IgAN 10.03.2026 4:15
Faculty: Suzuki Yusuke, MD, PhD Faculty: Dana Rizk, MD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0....
APRIL Uncovered: An Upstream Driver in IgAN 10.03.2026 6:15
Faculty: Dana Rizk, MD Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and...
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis 10.03.2026 6:15
Faculty: Richard Lafayette, MD, FACP IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphas...
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach 10.03.2026 5:00
Faculty: Richard Lafayette, MD, FACP Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g...
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN 10.03.2026 6:30
Faculty: Richard Lafayette, MD, FACP Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g...
Emerging Therapies in IgAN: Who Could Benefit the Most? 10.03.2026 7:30
Faculty: Richard Lafayette, MD, FACP Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <...
Emerging Evidence: IgAN Disease-Modifying Agents 10.03.2026 8:00
Faculty: Richard Lafayette, MD, FACP Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <...
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN 10.03.2026 6:30
Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier esc...
IgAN SOC: Strengths and Limits 10.03.2026 3:45
Faculty: Dana Rizk, MD Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0....
Mechanism-Based Targeting: Why APRIL Matters in IgAN 10.03.2026 4:15
Faculty: Suzuki Yusuke, MD, PhD Faculty: Dana Rizk, MD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0....
APRIL Uncovered: An Upstream Driver in IgAN 10.03.2026 6:15
Faculty: Dana Rizk, MD Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and...
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis 10.03.2026 6:15
Faculty: Richard Lafayette, MD, FACP IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphas...
Breaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026 06.03.2026 15:00
Faculty: Deepak Bhatt, MD, MPH, MBA, FACC, FAHA Faculty: Amir H. Hamrahian, MD 2025 delivered an expanded approval for Cushing syndrome for one agent, a complete response letter for another, and deeper insights on the prevalence of Cushing syndrome (or hypercortisolism) in people with difficult-to-control metabolic conditions. 2026 promises to be jam packed with further insights on Cushing syndrom...
Breaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026 06.03.2026 15:00
Faculty: Deepak Bhatt, MD, MPH, MBA, FACC, FAHA Faculty: Amir H. Hamrahian, MD 2025 delivered an expanded approval for Cushing syndrome for one agent, a complete response letter for another, and deeper insights on the prevalence of Cushing syndrome (or hypercortisolism) in people with difficult-to-control metabolic conditions. 2026 promises to be jam packed with further insights on Cushing syndrom...
So You Think You Want a TKI? 04.03.2026 6:00
Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The ser...
Who Needs a TKI? Identifying the Right Candidates 04.03.2026 5:45
Faculty: Roger A. Goldberg, MD, MBA Faculty: Christina Y. Weng, MD, MBA, FASRS This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The s...
To Implant or to Inject? 04.03.2026 5:15
Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series fur...
TKI: The New TKO for Retinal Diseases 04.03.2026 5:30
Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The ser...
The Struggle Is Real 04.03.2026 5:30
Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series fur...
Podobne podcasty
Słuchaj podcastu CME/CE w Replaio
Radio i podcasty w jednej aplikacji - za darmo, bez zakładania konta. Zainstaluj już dziś i nie przegap premiery
Replaio nie jest wydawcą podcastów; nazwy audycji, okładki i audio należą do ich autorów i są rozpowszechniane przez publiczne kanały RSS
